United States, Sept. 5 -- The U.S. Food and Drug Administration approved expanded use of Vonvendi [von Willebrand factor (Recombinant)] for routine preventative (prophylactic) use in adults (age 18 years and older) with all types of von Willebrand disease (VWD) and on-demand and treatment of bleeding episodes and perioperative use in children with VWD.Previously, Vonvendi was approved only for on-demand treatment of bleeding episodes and perioperative use in adults and preventative use only in adults with Type 3 VWD, the most serious type. Von Willebrand disease is a bleeding disorder in which a person's blood doesn't clot properly. People with the disease have low levels of von Willebrand factor (VWF), a protein that helps blood clot, or t...